DIN 02529653 — COSENTYX 300 MG
COSENTYX is a solution of Secukinumab marketed by NOVARTIS PHARMACEUTICALS CANADA INC. The full Secukinumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02529653
- Brand name
- COSENTYX
- Active ingredient
- Secukinumab
- Strength
- 300 MG
- Dosage form
- SOLUTION
- Route
- SUBCUTANEOUS
- Manufacturer
- NOVARTIS PHARMACEUTICALS CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Interleukin-17A antagonist (biological response modifier)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Secukinumab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02438070 | COSENTYX | 150 MG | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02547724 | COSENTYX | 150 MG | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02529661 | COSENTYX | 300 MG | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02525569 | COSENTYX | 75 MG | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |